ZIMMER BIOMET HOLDINGS, INC.
NYSE: ZBH·Warsaw, Indiana·CIK 0001136869
- Price
- $101.41
- Base IV
- $88.70
Valuation snapshot
At $101.41, the price sits between our base case ($88.70) and bull case ($140.16).
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $88.70
- 87% of the price · range $49.57–$140.16
- Price vs base case
- 14% above
- $101.41 against $88.70
- Base case · our researched forecast, 2026-11-05See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
The price has fallen 7.9% since this valuation was struck on 2026-11-05, so some of the gap opened up after these figures were set.
Whisker on the base case runs bear $49.57 to bull $140.16. Values per share.
Price against each value
- Bear case
- $49.57
- Price 105% above
- No growth
- …
- —
- Base case
- $88.70
- Price 14% above
What does Zimmer Biomet Holdings do?
Zimmer Biomet provides orthopedic reconstructive products, sports medicine tools, and robotic technologies to help surgeons treat patients with bone, joint, and soft tissue injuries.
It brought in $8.6B of sales in the 12 months to Sep 2026.
- Industry
- Healthcare
- Based in
- Warsaw, Indiana
- Trades on
- NYSE as ZBH
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 9¢ was left as profit after every cost, interest and tax. The biggest cost is sales, marketing and admin, 41¢ of every dollar.
- Making what it sells30¢
- Research and development5¢
- Sales, marketing and admin41¢
- Everything else it takes to operate11¢
- Interest and other costs3¢
- Tax1¢
- Left as profit9¢
Who pays Zimmer Biomet Holdings, and for what?
Zimmer Biomet sells implants and other products used to treat bone, joint and soft-tissue conditions, along with surgical, digital and robotic technologies. It earns revenue when hospitals, clinicians and distributors buy its products for surgical procedures.
Its customers include surgeons and other specialists, hospitals and surgery centers, distributors and medical purchasing groups.
Knees
40%Products for total, partial and revision knee replacement, including implants and robotic assistance.
Persona knee replacement implantsImage: Zimmer Biomet Holdings Hips
25%Products for first-time and revision hip replacement, including implants and bone cement.
G7 acetabular hip implant systemImage: Zimmer Biomet Holdings S.E.T.
26%Sports medicine, biologics, foot and ankle, upper extremities, trauma, and face, skull and chest reconstruction products.
JuggerKnot soft anchor systemImage: Zimmer Biomet Holdings Technology & Data, Bone Cement and Surgical
8%Digital and robotic technologies, bone cement, and products used by healthcare institutions during surgery.
ROSA knee planning interfaceImage: Zimmer Biomet Holdings
Where its work physically happens, beyond headquarters:
- Winterthur manufacturing site — Winterthur, Switzerland. This manufacturing site is in Switzerland, which Zimmer Biomet identifies as one of its most significant manufacturing locations outside the U.S.
- Galway manufacturing site — Galway, Ireland. The Galway site contributes to Zimmer Biomet’s Irish manufacturing footprint, which its 2025 Form 10-K identifies as among its most significant outside the U.S.
- Shannon manufacturing site — Shannon, Ireland. The Shannon site adds production capacity to Zimmer Biomet’s significant Irish manufacturing footprint.
- Asia Pacific regional headquarters — Singapore, Singapore. The office serves as regional headquarters for Asia Pacific, a segment that reported $1.26 billion in 2025 sales.
- Changzhou Biomet Medical Device — Changzhou, China. This medical-device site is part of Zimmer Biomet’s China footprint, which its 2025 Form 10-K identifies as one of its most significant manufacturing locations outside the U.S.
How is the business doing?
Sales grew from $7B in 2020 to $8.2B in 2025, about 3% a year.
Running the business leaves about 14¢ of each sales dollar as operating profit, up from 1¢ in 2020.
After paying for its upkeep and new investment, it had $1.6B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
Zimmer Biomet says it exists to ease pain and improve people’s quality of life worldwide.
“Alleviate pain and improve the quality of life for people around the world.”
What management says it is working on now:
People and culture
Management describes this as the company’s top priority and a foundation for its work.
Zimmer Biomet Announces Second Quarter 2026 Financial ResultsOperational excellence
Management lists improving how the company operates as a strategic priority.
Zimmer Biomet Announces Second Quarter 2026 Financial ResultsInnovation and diversification
Management says it is advancing innovation and diversifying the business, alongside continued momentum from new products.
Zimmer Biomet Announces Second Quarter 2026 Financial ResultsCommercial transformation
The company is changing its U.S. sales channel, including shifting many independent sales agents to employee roles, and says the transition is progressing as planned.
Zimmer Biomet Announces Second Quarter 2026 Financial Results
- 2026 reported revenue growth, 2026
- 3.9%–4.9%
- Zimmer Biomet Announces Second Quarter 2026 Financial Results
- 2026 organic revenue growth, excluding currency effects, 2026
- 2.25%–3.25%
- Zimmer Biomet Announces Second Quarter 2026 Financial Results
- Adjusted diluted earnings per share, 2026
- $8.47–$8.59
- Zimmer Biomet Announces Second Quarter 2026 Financial Results
- Gross annual operating expense reduction under the 2025 restructuring plan, By the end of 2027
- Approximately $175 million compared with 2024 baseline expenses
- Zimmer Biomet 2025 Form 10-K
What's changing right now?
Growth is slowing. In Q3 2026 it sold 3% more than a year earlier. The year before, quarters averaged 9%.
Its operating margin is narrower than a year ago: 15¢ per sales dollar, against 18¢.
Since Oct 2026 the share price has risen 4%, from $97.47 to $101.41.
Recently
December 31, 2024
Knee Franchise Revenue Growth changed to 4.5%
Zimmer Biomet 2024 Form 10-K Item 7
Coming up
November 4, 2026
Third-quarter 2026 results and conference call
The company plans to release its quarterly results and discuss them with investors.
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial ResultsLaunched by August 5, 2026; future adoption timing not specified
Next-generation ROSA Shoulder System
Zimmer Biomet reported U.S. clearance and completion of the first procedures using this robotic system; broader use could develop as surgeons adopt it.
Zimmer Biomet Announces Second Quarter 2026 Financial Results
Our own estimate moved too: the base case went from $56.99 to $88.70 a share between our last two valuations.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Strong competition and changing treatment choices
Competitors may bring out better or lower-priced products, while clinicians’ needs and treatment practices can change. If Zimmer Biomet does not develop and successfully introduce products that customers choose, sales and profitability could fall.
From the company's own filingsWould hit how fast sales growZimmer Biomet 2025 Form 10-K
Sales channel changes
Shifting U.S. sales agents to employees and changing sales coverage could disrupt customer relationships, leave gaps in coverage, raise costs or reduce sales if the transition is not managed well.
From the company's own filingsWould hit how fast sales growZimmer Biomet 2025 Form 10-K
Product approvals and regulation
Medical devices face extensive and changing rules. Delays in approval or problems meeting quality requirements could limit the company’s ability to sell or manufacture products.
From the company's own filingsWould hit how fast sales growZimmer Biomet 2025 Form 10-K
Healthcare cost controls and reimbursement
Hospitals, insurers and governments may limit coverage or push down prices. Measures such as China’s volume-based purchasing can reduce margins or demand for covered products.
From the company's own filingsWould hit how fast sales growZimmer Biomet 2025 Form 10-K
Manufacturing, suppliers and distribution
Interruptions at company sites or suppliers could prevent products from reaching customers. Some materials and services come from a limited number of sources, which can make replacements difficult to qualify quickly.
From the company's own filingsWould hit how fast sales growZimmer Biomet 2025 Form 10-K
Cybersecurity and data protection
Cyber attacks or system failures could interrupt operations, expose sensitive information, or affect connected products and services. The company also faces changing rules for patient data and artificial intelligence.
From the company's own filingsWould hit how fast sales growZimmer Biomet 2025 Form 10-K
Third-quarter 2026 reported revenue growth decelerated to 3.07% year-over-year from 9.30% in the first quarter of 2026.
From our researchWould hit how fast sales growZimmer Biomet Form 10-Q for the Period Ended September 30, 2026
Quarterly operating margins demonstrated volatility, dropping to 6.89% in Q4 2025 due to restructuring expenses.
From our researchWould hit how much of each sale it keepsZimmer Biomet Q4 2025 Financial Supplement
Is it a good business?
From 2009 to 2025 it earned between -0% and 14% on the capital invested in it, a median of 5%. Its cost of capital in the latest valuation is 6.9%; returns were above it in 2 of the 9 years.
From 2009 to 2025 it earned between -1% and 15% on its shareholders' equity, a median of 7%.
Over 9 years its operating margin ranged from 1¢ to 25¢ per sales dollar, a median of 13¢. Gross margin ran from 61¢ to 76¢.
Cost of capital 6.9%
It bought back shares: the count fell 3.7% in a year, so each remaining share owns a slightly bigger slice.
It owes $7.1B more than it holds in cash, about 6.1 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $101.41. Our put its value between $49.57 and $140.16, with $88.70 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $49.57
A cautious scenario where slowing procedure demand and persistent competitive pressure in surgical robotics hold annual sales growth near two percent and limit profitability to fifteen percent.
Base case, $88.70
A balanced scenario where steady demand for joint replacements and ongoing adoption of robotic surgical systems sustain sales growth near four percent with profitability stabilizing around seventeen percent.
Bull case, $140.16
An optimistic scenario where rapid adoption of surgical robotics and robust expansion in sports medicine and extremities accelerate annual growth above five percent and expand profitability toward twenty percent.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects more than we do.Price above value: 14%
For Zimmer Biomet Holdings to be worth today's $101.41, sales would need to grow about 6.2% a year. We assume 4.0%. Over the last 5 years, sales grew 3.7% a year.
Or, if sales grow 4.0% as we assume, the price works with a profit margin of 18.7% (we assume 17.0%).
Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.
Do you think sales can grow 6.2% a year?
Try your own numbersWe're moderately sure of this range: it scores 66 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $88.70 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average4.0%
- Operating margin17.0%
- Long-term growth rate2.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$88.70 -12.5%

